Great. Thanks, everybody, for joining this session. I'm Matt Taylor, the U.S. Medical Supplies and Devices Analyst here at Jefferies, and I'm very pleased to be joined by the management team from Globus, including Kyle Kline, who's the CFO, and Shagun Singh, who recently joined to head up the IR function. We'll have about 25 minutes for Q&A, which I'll kick off here with kind of a high-level question. Kyle, maybe you could talk about just Globus' positioning in the spine market, maybe talk about some of the other areas of musculoskeletal health that you're getting into, and how you think you can maintain that position versus some increasing competition.
Yeah. Thanks, Matt. At a high level, Globus is a musculoskeletal technology company. Our roots are essentially based in spinal implants. We were founded in 2003 by our founder and current Executive Chairman, David Paul. What we've done over the past 20-some years has been able to grow and scale this business in a way where we're essentially number two in the spinal implant market behind Medtronic. We own about a 20% share of the market. Spine is the core. We operate domestically and internationally as well, so we sell into about 65 different countries across the globe. Ancillary to that, and a key part of our differentiation, is our enabling technologies. We have an implant robot, we have an imaging system, as well as a navigation platform as well.
Our strategy is really pairing those implants with our enabling technologies to drive the best possible outcomes for our patients. Ancillary to that, we have a trauma and orthopedic business as well, growing quite strongly there. We've got five straight quarters of double-digit growth and expect that to be a strong contributor to top line here in the rest of 2026, 2027, and beyond. We've also have our most recent significant acquisition of Nevro, which introduced us to the pain space of spine, so spinal cord stimulation. That business, we believe, is a business that we had to spend time kind of getting it to right-size the business so that it was generating a profit, generating positive cash. It has done that here in the past 12 - 18 months, and now we're focused on driving top-line growth in that business as well.
Great. Maybe you could just talk about your innovation engine. I think you're legitimately one of the best innovative companies at scale that I've seen. You really come out with a lot of new products, especially versus your competitors. Talk about how you achieve that internally and how it's different than what you would see at one of the big other spine companies.
Yeah. Innovation for us is paramount to everything we do, right? We have a long-term goal of getting outcomes from 70% successful in the spine industry to try to work towards a way to get it to 95% successful. It's a very, very lofty goal, but it's something that we're very focused on. When we think about that, it's innovating in and around the implants, the enabling technologies, focusing on the entire proceduralization and how that procedure actually happens within spine, and then ultimately creating a long-term feedback loop of how do we utilize the data that we collect throughout the patient journey to inform better outcomes, to be able to create better predictive aspects of what type of procedure should we do, what type of implant, how do I pair that with my individual patient that I'm working on as well.
As Matt mentioned, we've got a very large portfolio. We consider we have the best bag of spinal implants in the industry, and we continue to invest heavily within R&D and efforts to continue to innovate.
Great. Maybe we could talk about a few of the innovations that are coming up here. You have a few product launches that you've highlighted. One of them that's really interesting is your foray with SCRIPT into custom or patient-specific implants. Could we talk about SCRIPT and your approach there to custom and what you think that could actually enable for both the surgeons and for outcomes?
Yeah. Patient-specific implants, the SCRIPT launch that we've just launched here in Q4, think about it as more than just one particular type of implant. There's actually seven different spacers within this launch, as well as a rod that will all be patient-specific. When you think about how that product will work, what you can imagine is there is a software that will allow the surgeon to go in, upload their scans and imaging of the patient, be able to create a plan for what that implant should ultimately look like, and flow that through into the actual manufacturing of that patient-specific implant.
If you think about the spine and the vertebrae, the idea here is that you have very specific contours on your vertebrae, and instead of putting your traditional spacer into that vertebrae to create that space, this patient-specific will actually match those exact contours of it, right? Better surface coverage, better ability to fuse, et cetera. That will allow us to drive better outcomes. That is a launch that I said was here in the fourth quarter. We started doing our first surgeries with that, with some of our surgeons here, and expect that to be a strong catalyst for growth in 2027.
Yeah, this is, I would say, a little bit of a bigger launch for you. I know you haven't sized it exactly, but maybe talk about this in the context of the other smaller launches and what kind of growth do you think this could produce in the future, or five years down the road, what percentage of your business could this be?
Yeah. When I think about SCRIPT and this launch, this is one of our bigger launches for the reasons that I've laid out. But when you think about where kind of the industry is going, I think we're in a spot in spine where that's ripe for even more innovation that we've had, right? The focus is really on how do we kind of look at things to look at ways to make outcomes become better. Pairing a patient-specific implant with our enabling technologies, I think, is really a key and an unlock for us as we move forward to take those implants, pair it not only with the precise measurements and precise contours of that implant to the patient, but also be able to use our enabling technologies to very precisely implant that implant into the patient.
Long term, yeah, you're right. We haven't broken out in terms of what that is in terms of a meaning for revenue in the short term or long term, but we do think that could be a big catalyst. We think the reimbursement rate on these patient-specific implants are high, as well as the ASPs that we'll be able to derive from this product.
Great. Maybe I'll pivot. Since we have you here, I wanted to talk a little bit about margins and cash flow. Globus actually really stands out versus a lot of medtech, but especially versus spine companies in terms of where your margins are and the amount of cash you're generating, which is useful to have. Could you talk about that journey through the last year? Nevro has been a big source of margin expansion as you've right-sized it. Can you talk about the further opportunities to synergize Nevro and get those margins higher, and other big margin drivers over the next couple years? I know there's a lot of gross margin initiatives that you have.
Yeah. I would take you back to 2023 when we combined Globus and NuVasive. We had significantly different margin profiles, so bringing those businesses together, it was first about rep retention and making sure that we fought off any potential revenue dis-synergies, but then also working through the P&L. We started with OPEX to try to identify and leverage synergies of bringing those two companies together. After we got through the OPEX synergies, we pivoted and focused on manufacturing initiatives. Pre-acquisition, we were a mid-70s gross profit company. Our goal is to get back to those mid-70s. Mid-70s for us has been defined as 72%-75%. We've been working here over the past handful of years to work on execution, and think about that as manufacturing initiatives, insourcing initiatives, supply chain and vendor contract renegotiation.
Over the past eight quarters, we've seen sequential improvement in our gross profit margin each sequential quarter, and about 100 basis points on average of improvement year-over-year for the past two years. We think that there's opportunity still there. The process to work through those manufacturing initiatives has taken a little bit longer than we initially thought, just as you work through the context of when and how do you bring different products in, how do you manage your vendor relationships, et cetera, and how do you work through those negotiations. But we think we've been very, very successful in that. I think there's opportunity to continue to expand on the gross margin line. As you think about the Nevro business and bringing that in, the focus there was really right-sizing that business from the get-go, and a lot of that was OPEX-related synergies.
We've seen some positive impact from a gross margin as well. Excuse me. As we move forward, that business is one that we want to grow top line on, which will ultimately create some leverage as we work through the P&L. When you think about gross profit paired with the operating leverage, that gives us a positive impact to leverage, or a positive impact to margins. An offset to that is something that we're going to be focusing on, and we started calling out about the middle of this year was reinvesting even more into product development. Tied into my comments on innovation, patient-specific enabling technologies, we're continuing to invest in product development. That'll be a little bit of a headwind to margin, offset by those tailwinds.
Great. Maybe we should unpack Nevro a little bit more and take us through the journey this year. You changed the sales force a bit, but have rehired folks and have basically talked about some stabilization through the second half of the year, and then potentially getting back to growth next year with a new product, a new IPG.
Yeah.
Is there anything that you would sort of add to that to help people understand the trajectory?
Yeah. I would step back and think about what Nevro was prior to acquisition. As their last year as a standalone company, they had $400 million of revenue and ultimately were a $100 million net loss on their P&L. We knew bringing that business in, we were going to have to make drastic changes to their internal approaches, their go-to-market, et cetera. As we work through that, what we saw 2025, that was an April 2025 acquisition. 2025, we executed synergies. We took a lot of cost out of OPEX. We redesigned how they were doing their product development function to better align with how Globus does it, as well as focused on trying to create just efficiency as we work through the manufacturing process. As we exited 2025, we were happy to announce that we achieved EPS accretion in the first nine months.
Our initial goal upon acquisition was to hit EPS accretion after 24 months. We well outpaced what we were expecting in terms of achieving that profitability. The pivot then that happened as we entered 2026 was the last piece that we wanted to kind of fix or change with Nevro, is to focus their sales force on sales growth, meaning that they are more targeted from a variable compensation perspective to build their revenue and grow their revenue year-over-year. What changed from historical Nevro was more of a fixed comp base with a smaller variable component. As we made that change, we had some turnover within the sales force, quite significant turnover in Q1. If you look at our results for the year, you will see that our top line has been impacted by that turnover.
In April and Q2 and throughout Q3, we have been focused on recruiting, hiring, training, and deploying those reps back out to the field, ultimately with the goal of driving higher trial volume, which is your leading indicator for a permanent implant, and that is really where the revenue comes from in terms of the Nevro business. We have seen success in bringing reps in, getting them trained, getting them deployed. What we called out in the Q3 earnings was that we saw some stability from a trialing perspective, which is our early indicator that we have got a stable base.
Now we have the ability to continue to deploy and get more trials, which will then ultimately lead to revenue. The positive, I would say, as you kind of think through that entire aspect is, even with revenue down in 2026 compared to 2025, we have been able to maintain margin. We are at about a 17.5% EBITDA margin for the year on the Nevro business, remain EPS accretive, and remain cash flow positive. As that revenue grows, you are going to see leverage from that business, and you will be able to drive further cash generation and further profitability.
Maybe just two follow-ups there. I think in Q3, the Nevro margins were 19.9%, and you have talked about the potential to bring them pretty close to your overall margin over time, so in the mid-30s basically. That would be over 100 basis points of margin expansion for the company with roughly 10% of revenue there. A, from here, is the main lever for margins really the growth, or are there other things that you can also do to grow margins?
Yeah. I think there's little pieces around the edges, but I think about key synergy actions, I would say those actions have taken place, and you've seen those in the P&L at this point. I think this is really more of a leverage perspective and being able to grow top-line sales.
The good news there is you do have the new IPG next year. So maybe talk about what that is, when it's launching. In general, new products in this neuromodulation space have driven nice growth for all the players when they've launched them. But talk about the materiality of this one for you.
Yeah. So I think this is important for us. It's called HFX Elite. So if you go back a few years to when Nevro was a standalone company versus the past 18 months of being under our ownership, this is really the first launch within Nevro within the past couple of years. So, meaningful from that standpoint, meaningful to get a new IPG out into the market. The key differentiator here is the bolus technology, which essentially controls when and how that stimulation goes and the therapy goes to the patient versus your typical stimulation, which is essentially a constant stimulation. That is really the differentiator there. As we look ahead to 2027, we do think that that will drive some growth within the business, but we also think those reps kind of getting trained on board and deployed, that'll be part of the growth story as well.
You should expect as we get into 2027, right, a lot of that will be a crawl, walk, run when we think about our business. It won't immediately turn on. We'll continue to see the benefit of sales reps and trialing and permanent conversions. I would say that's a first-half launch in terms of the new IPG, so expecting to have some impact in the back half of the year.
Great. Maybe we could just touch on spine market growth. There has been some debate there as to whether we are seeing a material slowdown, just with some electivity in spine. How much of that do you think we are actually seeing, or are there other things at play? You have tough comps and things like that have been impacting you, and the competitors have had issues with biologic attachment rates. It is a little hard to see.
Yeah.
What do you think the market is growing, and has there been a big effect from macro pressure?
Yeah, and we have been getting that question a lot. It seems to be a key theme here at the conference with the questions that we have received. The way I would answer that is, one, I think you have to look at our specific situation, and to your point, Matt, on tough comps. If you go back and think about 2025 and the back half of 2025, our domestic spine business grew at 10% for the back half. Typically, we are targeting somewhere in the mid to high single digits in terms of growth. We did have some significant growth. Part of that was due to competitive rep recruiting and really getting a bolus of revenue from those competitive rep recruits. As you enter 2026, what our expectation was is you would have higher growth in the first half, a little bit lower in the second half because of those tougher comps.
The way we are looking at it and talking to investors about it is, in order to normalize some of those tough comps, you should really look at it on an average two-year growth basis. If you look Q1, Q2, Q3 consistently on an average two-year growth basis, we have been growing at about 6%. So feel positive about where the business is, where the business is headed from that standpoint. When we talked in Q3 about what was happening in the business and why some of the lower growth was there, it was, A, those tougher comps and kind of stabilizing for that two-year period. The other piece of it was focused on what could we control, because we typically, and our strategy is to grow above and beyond market growth.
Regardless of what market grows, our plan is through product innovation and new product launches, through competitive rep recruiting, as well as enabling technology placements and the pull-through from that placement, that we can drive above-market growth in the spine business. We did hear some of the commentary around lower market growth in general. As we took the parts and pieces of what we expected in Q3, and what we could quantify and calculate, specifically around product launches and competitive rep recruiting, and compared that to what we expect the market is generally growing, which we say is somewhere in the 3%-4% range, we had a small remainder that is potentially a market driver, but nothing that would be significant enough that took us outside of the range of typical kind of market growth. That's the key way we kind of thought about it.
The other thing I'll say about spine in general is, the way we view it is, by the time you get to spine surgery, you've exhausted all other methods of how you deal with that pain, right? So whether it was some kind of medication, whether it was stimulation, whether you're getting some type of injection, by the time you get to the point where your surgeon recommends surgery, you have no other options. So even if there was some type of market dynamic, we view that as something that gets delayed for a relatively short-term period of time, like at most within a couple of months, because that patient does need that surgery. So even if there was a slight bit more of a delay, we don't think that will really impact the broader market here in Q4 and beyond.
Maybe we should just touch on enabling tech as well, because you've been really leading the charge there with strong navigation, imaging, and leadership in robotics. Could you talk about your differentiation there? And also, the change in the go-to-market model this year has really produced nice results in terms of the unit growth, which ultimately leads to lots of product pull-through and good cash flow in the future.
Yeah.
Let's talk about differentiation and then why you're seeing so much growth this year, I guess.
Our start into enabling technologies was back in Q4 of 2017 with our robotic launch. From there, we've continued to enhance the initial robot. The initial robot was primarily for fixation and screw placement. We've evolved that and introduced software to get it into interbody placement, so your cages and your spacers, as well as put other software modules on there Excelsius Cranial would be another one to perform cranial surgery. We've continued to enhance that base robot as well as add other capital components to it. So we have our E3D or our imaging system that does our imaging and our scanning, and then we also have a navigation platform called the [ExcelsiusHub] as well. So we've continued to broaden and expand that category and those platforms in there.
When I think about the success that we've had, I go back to that initial robot being launched in 2017, and we have made improvements, but we're still on that initial generation of the robot. I think the durability and our ability to continue to get units out into the field and still essentially be the standard of excellence when it comes to spine robotics really stands the test of time, and that's what tells you that we have a really strong offering in terms of our robotics capabilities. When we think about the model shift, which we talked about probably about a year ago, it was historically we've been able to sell our enabling tech through cash deals upfront, cash sales, recognize revenue upfront in the period of the sale.
What we identified is that we went through a period in 2025 where the sales cycle was getting a little bit longer, and I think it was because there was, A, more enabling tech out on the market for our hospital customers to evaluate, but also more ways to acquire capital than ever before. What we identified is, although we had always offered alternatives to acquiring our capital outside of just upfront cash, that maybe the hospitals weren't as aware or we weren't selling as much of these alternative acquisition models. So think rentals, leases, volume-based arrangements, et cetera. So to Matt's point, that's been a focus of ours over the past 12 months. This year, we've actually seen a really, really strong uptake.
Keith had called out in our Q3 call, if you look at our robot and our ExcelsiusHub platform, you'd actually see year-to-date growth in total units of 73%. So if you look at the sales dollars perspective, not as significant because there's less cash sales, but the units have really expanded. When we think about the importance of the unit expansion, it's really thinking about what's the recurring revenue that we can get off of that. So one is implant volume, right? Pull-through revenue. If that robot's there and using our implants, you're going to drive more implant volume. Two is the service revenue, right? As more units are out there, we get our customers after the first year of warranty, we get them on a service contract, have that recurring revenue.
If you also think about these structures with these alternative deals, the revenue on that base robot is recognized over time. Instead of getting a bolus of revenue in a period which causes more lumpiness, you actually have a period of revenue, and it is going to be tied to the contract, but three to five years that you recognize the revenue there. It is very important for us to continue to strategically get that capital out into the field to drive all that recurring revenue.
Maybe just to wrap up, I will ask you one on cash flow, because your cash flow and your cash flow yield are very strong, and you have been buying back a ton of stock, but also recently did some tuck-in deals. Can you talk about the balance of capital allocation priorities, your goals to continue with the buyback, and what did that tuck-in bring you?
Yeah. At a high level, we continue to reiterate our priority around capital allocation. Number one, we always want to invest back into ourselves. That was a focus of the discussions the past two quarters in putting even more investment into product development to feed innovation and feed the next new products and ultimately drive additional sales growth. We are going to focus on CapEx in terms of our manufacturing initiatives, as well as getting more instruments and sets out into the field into the hands of our reps. Third has been share repurchases. If you look at year to date, we are at about $280 million worth of share repurchases. About 50% of our free cash flow has been deployed through share repurchases. So we intend for that to continue to be a key part of how we bring value back to the shareholders.
Finally, as you touched on, M&A. We did two smaller deals this quarter. One, Synaptive, which is cranial, and think of Exoscope and that equipment. We think that was a good technology play for us. We are already in with a lot of the neurosurgeons that are doing both spine and cranial, so we looked at that as a good place to get in and to get into the cranial market and to pair with the cranial platform on our robot that currently exists. Higgs Boson was the other acquisition that we made. Think of it as more of an AI type company.
As we think about building out the future state of what we are looking for in terms of proceduralization, enabling technologies, and a feedback loop of information between that will help inform patient selection and hopefully drive better outcomes in our strategy of getting to that 95% good outcomes for our patients.
Great. It is a good place to wrap up. We need more AI plays in medtech, so that is great. Thanks a lot for your time, and thanks everybody for your attention and interest in Globus. Appreciate it.
Thanks, Matt.